ID   OCUM-8/GEM
AC   CVCL_II63
DR   Wikidata; Q54931838
RX   PubMed=21997136;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_175901; Gemcitabine (Gemzar).
CC   Sequence variation: Gene fusion; HGNC; HGNC:1681; CD44 + HGNC; HGNC:5465; IGF1R; Name(s)=CD44-IGFR1; Note=In frame. CD44 exon 1 fused to IGF1R exon 12 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C9159; Gastric diffuse adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8389 ! OCUM-8
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 8
//
RX   PubMed=21997136; DOI=10.1038/bjc.2011.397; PMCID=PMC3242520;
RA   Yashiro M., Qiu H., Hasegawa T., Zhang X., Matsuzaki T., Hirakawa K.;
RT   "An EGFR inhibitor enhances the efficacy of SN38, an active metabolite
RT   of irinotecan, in SN38-refractory gastric carcinoma cells.";
RL   Br. J. Cancer 105:1522-1532(2011).
//